{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-023114","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.836840+00:00","generated_at":"2026-06-11T17:03:51.210863+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vistagen reports positive Phase 3 PALISADE-2 fasedienol results for SAD; Q1 net loss $6.9M","bullets":["Phase 3 PALISADE-2: fasedienol met primary endpoint (SUDS LS mean diff -5.8, p=0.015) and secondary CGI-I responder rate (37.7% vs 21.4%, p=0.033).","Net loss for Q1 FY2024 was $6.9M, down from $19.8M YoY; R&D expense decreased $11.1M to $4.2M.","Cash $9.6M at June 30, 2023; raised ~$16.9M from shares in July/Aug 2023, with additional $15.2M expected by Aug 14.","Itruvone (PH10) moving to Phase 2B for MDD after successful US Phase 1; PH80 Phase 2A showed significant hot flash reduction (p<.001).","Planning Phase 3 PALISADE-3 and FEARLESS in 2024; fasedienol well-tolerated with no serious AEs."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-023114","json":"https://secwatch.observer/filing/0001437749-23-023114.json","markdown":"https://secwatch.observer/filing/0001437749-23-023114.md","text":"https://secwatch.observer/filing/0001437749-23-023114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923023114/0001437749-23-023114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923023114/vtgn20230810_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:03:51.210863+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d368a04ea6b24e45d616bbf29f9ec87be3a5e8ee","claim":"Vistagen Therapeutics, Inc. reported financial results for fiscal year 2024 first quarter ended June 30, 2023.","evidence_excerpt":"On August 10, 2023, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release to announce the Company’s financial results for its fiscal year 2024 first quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923023114/0001437749-23-023114-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2024 first quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}